GenovefaAPapanicolaouMD

Infectious Disease • New York, NY

Professor, Medicine, Weill Cornell Medical College

Join to view full profile

Dr. Papanicolaou is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Papanicolaou's full profile

Already have an account?

Office
530 East 74th Street
New York, NY 10021

Education & Training

Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalFellowship, Infectious Disease, 1994 - 1996
Roger Williams Medical CenterFellowship, Infectious Disease, 1993 - 1994
Newton-Wellesley HospitalResidency, Internal Medicine, 1990 - 1993
University of AthensClass of 1985

Certifications & Licensure

NY State Medical License 1996 - 2026
NJ State Medical License 2021 - 2025
American Board of Internal Medicine Infectious Disease

Clinical Trials

The Role of Genetic Polymorphisms in Innate Immune Response Genes in Susceptibility to Infections Start of enrollment: 2003 Feb 01
Completed
Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Start of enrollment: 2010 Sep 09
Completed
Phase 4
A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients Start of enrollment: 2013 Aug 01
Completed
Phase 3
Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection Start of enrollment: 2014 Mar 01
Completed
Phase 3
Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT) Start of enrollment: 2017 May 04
Completed
Phase 2
A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection Start of enrollment: 2019 Jul 19
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

134 citations
Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: A randomized, dose-ranging, double-blind, ...
Genovefa A. Papanicolaou, Fernanda P. Silveira, Amelia Langston, Marcus R. Pereira, Robin K. Avery
Clinical Infectious Diseases. 2019-04-08
56 citations
American Society for Transplantation and Cellular Therapy Series: #3-Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation.
Morgan Hakki, Samuel L. Aitken, Lara Danziger-Isakov, Marian G. Michaels, Paul A. Carpenter
Transplantation and Cellular Therapy. 2021-09-01
28 citations
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.
Sunwen Chou, Sophie Alain, Carlos Cervera, Roy F Chemaly, Camille N Kotton
The Journal of Infectious Diseases. 2024-02-14

Press Mentions

Exploring the Potential of Convalescent Plasma for COVID-19 TreatmentMay 15th, 2020
New Cytomegalovirus Antiviral Shows Efficacy in Phase 3 Clinical TrialJune 22nd, 2017

Grant Support

Site Specific Integration By Adeno Associated VirusNational Institute Of Allergy And Infectious Diseases2000–2003
Site Specific Integration By Adeno Associated VirusNational Institute Of Allergy And Infectious Diseases1999